Núcleo de microbiota en el cáncer de pulmón central con enriquecimiento estreptocócico como posible marcador de diagnóstico by Bello, S. et al.




































ore  Microbiota  in  Central  Lung  Cancer  With  Streptococcal
nrichment  as  a  Possible  Diagnostic  Marker
alvador  Belloa,∗,  José  J.  Vengoecheaa,  Manuel  Ponce-Alonsob, Ana  L.  Figueredoa, Elisa  Mincholéa,
ntonio Rezustac,  Paula  Gambód,  Juan  Manuel  Pastore,  Javier  Galeanoe, Rosa  del  Campob,f
Department of Pulmonary Medicine, Miguel Servet University Hospital, CIBERES, Instituto de Investigación Sanitaria (ISS) Aragón, Zaragoza, Spain
Department of Microbiology, Ramón y Cajal Health Investigation Institute (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain
Department of Microbiology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria (ISS) Aragón, Zaragoza, Spain
Department of Pathology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria (ISS) Aragón, Zaragoza, Spain
Complex Systems Group, Universidad Politécnica de Madrid, Madrid, Spain
University Alfonso X El Sabio, Villanueva de la Cañada, Madrid, Spain
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a  b  s  t  r  a  c  t
Background:  Dysbiosis  in  lung  cancer  has  been  underexplored.  The  aim  of  this study  was  to  define  the
bacterial  and fungal  microbiota  of  the  bronchi  in central  lung  cancer  and  to compare  it  with  that  of  the
oral  and  intestinal  compartments.
Methods: Twenty-five  patients  with  central  lung  cancer  and  sixteen  controls  without  antimicrobial  intake
during  the previous  month  were  recruited.  Bacterial  and  fungal  distribution  was  determined  by massive
sequencing  of bronchial  biopsies  and  saliva  and  faecal  samples.  Complex  computational  analysis  was
performed  to  define  the core  lung  microbiota.
Results: Affected  and  contralateral  bronchi  of  patients  have  almost  identical  microbiota  dominated
by  Streptococcus,  whereas  Pseudomonas  was  the  dominant  genera  in  controls.  Oral  and  pulmonary
ecosystems  were  significantly  more  similar  in patients,  probably  due  to microaspirations.  Streptococ-
cal  abundance  in  the  bronchi  differentiated  patients  from  controls  according  to  a ROC  curve  analysis
(90.9%  sensitivity,  83.3%  specificity,  AUC =  0.897).  The  saliva  of  patients  characteristically  showed  a  greater
abundance  of Streptococcus,  Rothia,  Gemella  and  Lactobacillus.  The  mycobiome  of  controls  (Candida)  was
significantly  different  from  that of  patients  (Malassezia).  Cancer  patients’  bronchial  mycobiome  was
similar  to their  saliva,  but  different  from  their  contralateral  bronchi.
Conclusions: The  central  lung  cancer  microbiome  shows  high  levels  of  Streptococcus,  and  differs  signifi-
cantly  in  its  composition  from  that  of  control  subjects.  Changes  are  not  restricted  to  tumour  tissue,  and
seem  to  be the consequence  of  microaspirations  from  the  oral  cavity.  These  findings  could  be useful  in
the  screening  and even  diagnosis  of  this  disease.
©  2020  SEPAR.  Published  by Elsevier  España,  S.L.U.  All rights  reserved.
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áncer  de pulmón
icroaspiraciones
treptococcus
r  e  s  u  m  e  n
Antecedentes:  La  disbiosis  en  cáncer  pulmonar  no  ha  sido suficientemente  estudiada.  Los objetivos  de  este
estudio  fueron  definir  la microbiota  bacteriana  y fúngica  de  bronquios  con cáncer  central  de  pulmón,  y
compararla  con  la  del  compartimento  intestinal  en  heces  y saliva.
Abbreviations: ASV, amplicon sequence variant; AUC, area under the curve; COPD, chronic obstructive pulmonary disease; FISABIO, Fundación para el Fomento de la
nvestigación Sanitaria y Biomédica de la Comunitat Valenciana; IL, interleukine; LDA, linear discriminant analysis; LEfSE, linear discriminant analysis effect size; PCoA,
rincipal coordinate analysis; PERMANOVA, permutational multivariante analysis of variance; QIIME, Quantitative Insights Into Microbial Ecology; ROC, receiver operating
haracteristic.
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Métodos:  Se  reclutaron  25 pacientes  con  cáncer  central  de  pulmón  y 16  controles  sin  exposición  antibiótica
durante el  mes  anterior.  Se determinó  la  composición  de  bacterias  y hongos  en biopsias  de  bronquio,  saliva
y heces.  Se  realizó  un análisis  computacional  para  definir  el núcleo  de  microbiota  del  pulmón.
Resultados: Los  bronquios  afectados  y  contralaterales  de  pacientes  presentaron  una  microbiota  similar
dominada por Streptococcus,  mientras  que  Pseudomonas  destacó  en  los  controles.  Los  ecosistemas  orales  y
pulmonares fueron  significativamente  más  parecidos  en  pacientes,  probablemente  debido  a microaspira-
ciones. La  abundancia  bronquial  de  estreptococos  permitió  diferenciar  a los  pacientes  de  los  controles
mediante una  curva  ROC  (90,9%  de sensibilidad,  83,3%  de  especificidad,  AUC  =  0,897).  La  saliva de  los
pacientes presentó  mayor  abundancia  de  Streptococcus,  Rothia,  Gemella  y  Lactobacillus.  El micobioma  de
los controles  (Candida)  fue significativamente  diferente  al  de  los  pacientes  (Malassezia),  con  los  bronquios
afectados por  el  cáncer  similares  a su saliva,  pero  diferentes  de  sus  bronquios  contralaterales.
Conclusiones: En  el  cáncer  de  pulmón  central  hay  enriquecimiento  de  Streptococcus,  y su composición  es
significativamente diferente  de  sujetos  control.  Las  alteraciones  no  se  limitan  al  tejido  tumoral,  y parecen
ser consecuencia  de  microaspiraciones  desde  la  cavidad  oral.  Estos  hallazgos  podrían  ser  útiles  para  la










































Culture-independent techniques have revealed the composition
f a stable microbiota within the distal airways; and although nor-
ality criteria have not yet been established, atypical compositions
inked to certain respiratory diseases have been detected.1 Dys-
iosis is typically detected surrounding tumours tissues, and this
rait has been poorly explored in the respiratory airway tissues,2,3
ostly using surgical samples.4–8 An understanding of the micro-
iota is necessary to decipher its possible causal role in cancer, and
lso to elucidate the prognosis and response to immunomodulatory
herapies, because microorganisms and/or their metabolites shape
he local microenvironment, influence the immune response, and
mpact the final battle against cancer.9 Finally, the presence and/or
bundance of specific bacteria could be used as a biomarker, as
ccurs with Streptococcus gallolyticus sbsp. gallolyticus in the col-
rectal cancer.10
The aims of the present study were to define the bacterial and
ungal microbiota of central lung cancer, in relation to the cor-
esponding contralateral bronchus and compared with controls
ithout cancer history, also defining the core of those microbio-
as; and to correlate the pulmonary microbiota in lung cancer with
he salivary and faecal compartments.
ethods
atients and samples
Twenty-five patients (24 men, mean age of 68 years) diag-
osed with central lung cancer, directly visible and biopsied by
ronchoscopy, were recruited (Table 1). The exclusion criteria
ncluded the intake of antibiotics, pre or probiotics, and systemic
orticoids during the previous 4 weeks; acute infection; radio or
hemotherapy in the last year, and immunodeficiency. Tumours
ere histologically classified into non-small cell lung cancer (n = 18,
ncluding 10 squamous, 4 adenocarcinoma, and 4 undifferenti-
ted); and small cell lung cancer (n = 7). Each patient contributed
ith 4 samples: (i) saliva collected from a rinse with sterile dis-
illed water, prior to the bronchoscopic procedure, (ii) biopsies of
ffected, and (iii) contralateral bronchi, and finally (iv) a faecal sam-
le (provided by 18 out of the 25 patients). The nasal route, or oralPlease cite this article in press as: Bello S, et al. Core Microbiota in C
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016
f not possible, with local instillation of lidocaine were used for
ronchoscopies. Prior to the tumour sampling, biopsies for micro-
iota determination were obtained from contralateral non-affected
issues.PAR.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los  derechos  reservados.
Simultaneously, 16 controls without history of cancer were
included, and each contributed the following: (i) oral microbiota
and (ii) a single biopsy of their healthy bronchi. Controls without
respiratory symptoms (except 2 with chronic cough) underwent
bronchoscopy for non-cancer related indications (benign tracheal
stenosis 9, fake haemoptysis 3, chronic cough 2, control of a previ-
ous endobronquial hamartoma resection 1, and dyspnoea 1), and
all of them had normal spirometries. All samples were immediately
frozen at −80 ◦C after collection.
Microbiota composition
Total DNA was obtained by the QiaAmp kit (Qiagen) from
the biopsies, from the pellet of saliva after centrifugation, and
from 200 l aliquots of a solution of 0.5 gr of faeces in 5 ml  of
water. Bacterial composition was determined by PCR amplifica-
tion of the 16S rDNA V3-V4 region using published primers,11
whereas the mycobiome was  only analyzed in bronchial and
saliva of the 16 controls and in a subset of 6 patients by ampli-
fication of the ITS-1 region.12 PCR products were submitted to
massive sequencing (2× 300 bp) on a MiSeq (Illumina, San Diego,
CA, USA) platform, at FISABIO (Valencia, Spain). Raw sequence
data were deposited in GenBank (BioProjects PRJNA586753 and
PRJNA586768. QIIME2 software suite (2019.1 distribution)13 and
LEfSE14 were used for analysis, and adequate negative sequenc-
ing controls were added in each process and run. A computational
analysis has developed to define the microbiota core that was
present in at least 95% of the individuals. This analysis is available
at https://github.com/JJ-Lab/Cancer Lung Microbiota website.
Results
Sample filtering
Three  samples from affected bronchi (patients 23, 24, and 25)
and four samples from control bronchi (controls 2, 3, 7, and 16)
were excluded of the analysis since they did not reach minimal
sequencing depth requirements (>1000 reads/sample).
Alpha  diversity
Alpha diversity indexes, as Chao1 and Shannon, express theentral Lung Cancer With Streptococcal Enrichment as a Possible
/j.arbres.2020.05.034
mean diversity in microbial species in a single community, with
the highest values corresponding to the greater number of species
(richness). Faeces and saliva had similar alpha diversity val-
ues, while bronchi were significantly more diverse according to
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Table  1
Demographic and clinical data of patients with lung cancer and healthy controls, differentiating between the entire control population (n = 16) and those included in the








Age (years mean ± SD) 67.7 (12.8) 51 (14.4) .0003 52.1 (14.9) .002
Male  (%) 24 (96%) 8 (50%) .002 6 (50%) .003
Active  smoker (%) 14 (56%) 3 (19%) .02 1 (8.3%) .01
Exsmoker  (%) 11 (44%) 4 (25%) .3 4 (33.3%) .7
Never  smoked (%) 0 (0%) 9 (56%) <.001 7 (58.3%) <.001
Familiar  cancer (%) 8  (32%) 11 (69%) .04 8  (66.6%) .07
Other cancer (%) 2  (8%) 3 (19%) .3 3 (25%) .3
Hypertension  (%) 13 (52%) 3 (19%) .05 3 (25%) .1
Diabetes  (%) 9 (36%) 0 (0%) .006 0 (0%) .01
Dyslipemia  (%) 16 (64%) 5 (31%) .08 5 (41.6%) .1
Annual  visit to dentist 3 (12%) 10 (63%) .001 8 (66.6%) .001
Lack  of teeth 21  (84%) 12 (75%) .6 9 (75%) .6
COPD (%) 12 (48%) 0 (0%) .001 0 (0%) .003
Mild  (FEV1 > 80%) 3 (25%) – –
Moderate (FEV1 50–79%) 8 (67%) – –
Severe (FEV1 < 50%) 1  (8%) – –
Asthma (%) 0 0 0
Interstitial lung disease 0 0 0
Respiratory function test
Normal (%) 10 (40%) 16 (100%) <.001 12 (100%) <.001
Obstructive  (%) 7 (28%) 0 (0%) .03 0 (0%) .07
Mixed  (%) 5  (20%) 0 (0%) .1 0 (0%) .1
































FCV  mean ± SD 89.3 (14.3) 103.7 (1
FEV/FCV  mean ± SD 73.2 (12.9) 78.7 (5
tatistically significant values that can differentiate control cases are highlighted in
aith’s PD index (which specifically assessed phylogenetic diver-
ity) (Fig. 1). The diversity of saliva was comparable in patients and
ontrols.
icrobiota composition
Beta  diversity analysis compares the microbiota composition
etween different samples, and use to be referred to phyla (Fig. 2)
nd genera levels (Fig. 3). Patients’ saliva presented a higher density
f Firmicutes and Actinobacteria to the clear detriment of Pro-
eobacteria, and this pattern was reproduced in the affected and
ontralateral bronchi. Faecal samples had a remarkably high pro-
ortion of Firmicutes (>75%) (Fig. 2).
aliva
Up to 213 genera were detected in saliva samples, with 13
omprising the majoritarian in both controls and patients: Strep-
ococcus (19% and 23%, respectively), Prevotella (15–13%), Rothia
4–7%), Veillonella (7–8%), Neisseria (6–4%), Porphyromonas (6–4%),
aemophilus (6–2%), Gemella (3–5%), Fusobacterium (5–3%), Allo-
revotella (4–1%), Actinomyces (2–2%), Granulicatella (1–2%), and
eptotrichia (1–2%). The remaining genera represented less than 1%
f the total microbiota abundance.
Saliva microbiota core from patients and controls were similar,
nd although significant differences on the bacterial proportions
ere detected (Figs. 3 and 4, and supplementary material), that
ifferences are linked to relative abundance of common taxa and
o to presence or absence of specific taxa. Streptococcus, Rothia,
emella and Lactobacillus abundances are capable of distinguishing
he saliva of patients from controls.
ronchiPlease cite this article in press as: Bello S, et al. Core Microbiota in C
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016
More than 450 bacterial genera were identified with different
istribution among patients and controls, while the microbiota
f the cancer-affected bronchus was almost identical to its con-
ralateral counterpart (Figs. 3 and 4, and Supplementary material)..001 101.9 (10.3) .01
.1 79.8 (8.4) .2
Particularities  depending on the histological type of cancer were
not detected.
Lung cancer-related genera were Streptococcus (19% in affected
bronchus and 24% in contralateral), Prevotella (9–9%), Blautia
(5–4%), Veillonella (4–5%), Rothia (3–4%), Neisseria (2–3%), Gemella
(2–2%), and Porphyromonas (2–2%). Health bronchi from control
group was  dominated by Pseudomonas (21%), followed by Strepto-
coccus (8%), Actinobacter (6%), Veillonella (4%), Prevotella (3%), Delftia
(3%), Janthinobacterium (3%), Escherichia-Shigella (2%), Haemophilus
(2%), and Neisseria (2%).
Streptococcal  abundance characterizes the microbiota of patients
Streptococcus is a genus within the Firmicutes phylum that has a
complex taxonomy. Our results showed that bronchial streptococ-
cal abundance systematically distinguished patients from controls
Up to 95 different amplicon sequence variants (ASV) assigned to
Streptococcus were identified among all samples, and their particu-
lar distribution allowed us to hypothesize an exchange between
oral and bronchial ecosystems (Supplementary material) Faeces
were the most remote niche, with saliva and bronchi also distant. It
is important to note that >95% of the ASV detected in the patients’
bronchi were also present in their saliva, while on the contrary
only 36% from saliva were also in the lung, indicating that saliva is
the main source of pulmonary Streptococcus. An ROC curve repre-
senting Streptococcus bronchial abundance distinguished patients
from controls, particularly when a relative abundance > 14.6% pre-
dicted lung cancer with 90.9% sensitivity and 83.3% specificity
(AUC = 0.897) (Fig. 5). Unfortunately, this result was not reproduced
in saliva.
The comparison of the whole microbiota in samples within each
individual revealed that saliva and bronchi of patients with lung
cancer were significantly the closest ecosystems (p < 0.001) (Fig. 5).entral Lung Cancer With Streptococcal Enrichment as a Possible
/j.arbres.2020.05.034
Mycobiome composition
Fungal  characterization through ITS1 sequencing was  deter-
mined in the 16 controls (saliva and bronchus) and a subset of
Please cite this article in press as: Bello S, et al. Core Microbiota in Central Lung Cancer With Streptococcal Enrichment as a Possible
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016/j.arbres.2020.05.034
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Fig. 1. Analysis of alpha diversity by sample location using Chao1, Shannon, and Faith’s PD indexes. Significant differences (p < 0.05) between groups are highlighted by
asterisks.
Fig. 2. Bacterial phyla distribution in each sample showing a high abundance of Firmicutes in lung cancer patients, combined with lower proportions of Proteobacteria.
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ig. 3. Microbiota core of the most abundant genera accounting for 90% of total. The
ere determined by their frequency.
 patients (saliva, affected and contralateral bronchi). Regarding
o alpha diversity, differences in Chao1 index were not observed,
hereas Shannon was significantly higher in affected bronchi from
atients compared to controls (p < 0.03) in accordance with the
esults obtained for bacteria (Supplementary material).
Affected bronchi and saliva from patients have similar fungal
omposition, but different from both their contralateral bronchi
p < 0.006), and the bronchi (p < 0.001) and saliva (p < 0.007) from
ontrols. This trend supports the aforementioned bacterial findings,
hich also suggest an interconnection between both anatomical
cosystems in lung cancer patients. A differential abundance anal-
sis between affected bronchi from patients and from controls
howed an enrichment of Malassezia in patients, whereas controls
ad a higher abundance of Candida (Fig. 6).
iscussion
The role of microbiota in carcinogenic processes has not yet
een elucidated and will probably be different for each tumour and
ocalization. Recent data clearly indicate that the microbiota con-
ributes to the prognosis of cancer and determines the response
o treatments, particularly responses to the new immunomodu-
ation therapies.9,15 Criteria for the normal composition of lung
icrobiota have not yet been established, but the available data
ndicate that their composition in cancer patients differs con-
iderably from that of healthy individuals.2–8 Sampling in the
espiratory system requires invasive methods, and here we have
haracterized the respiratory microbiota surrounding central lung
ancer by direct sampling of the tumour tissue by bronchoscopy.
ur results reinforce the previously known particularities of the
ung microbiota, which considerably differ from oral and stool
icrobial communities.16 Our results also allowed us to rule out
ignificant contamination with the upper microbiota during the
ronchoscopy, as other authors had previously suggested.17–19
oreover, we  considered strict inclusion criteria to avoid the pos-
ible bias of antibiotic or corticosteroid therapy, and the bacterial
xchange between the anatomically separated niches such as salivaPlease cite this article in press as: Bello S, et al. Core Microbiota in C
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016
nd faeces. Finally, the mycobiome composition of central lung
ancer was studied.
Lung  microbiota has been described based on health status
r a lung cancer diagnosis in sputum,20 bronchoalveolar lavage,5ance of each genus is represented by the circle size and the numbers of connections
protected specimen brushing,6 cytological brushing,21 and sur-
gical tissue.7,8,22 Our major contribution is the depiction of the
microbiome surrounding central cancer via direct sampling, but our
results are not necessarily applicable to the microbiota of the dis-
tal airway. Curiously, higher diversity indexes have been detected
in bronchi than in faecal or oral compartments, contrarily to the
biomass decreases from upper to lower tract described in healthy
people.19
We found significantly higher alpha diversity values in cancer
than in the control group, whereas other authors have published
analogous8 and opposing results.5,6,22 Moreover, advanced can-
cer stages16 and reduced recurrence-free survival and disease-free
survival22 have been associated with higher values of alpha diver-
sity. In that sense, 80% of our patients were at tumour stage III or
IV, and their mean survival was  only of 198 days in the follow
up. Furthermore, other factors such as environmental exposure,
residence in high-population density areas,4,16 and pack-years of
tobacco smoking, can increase the biodiversity of the lung micro-
biota, whereas chronic bronchitis reduces it.16 All our patients had
been smokers, while most of the controls (56%) had not (Table 1).
In  terms of beta diversity, cancer affected and contralateral
bronchi had very similar compositions, probably reflecting the
environmental influence which is not restricted to the cancer
area.2,6,21,22 Although the limited size of our sample prevents us
from reaching solid conclusions, no differences were detected in
the composition of the bronchial microbiota as a function of the
histological variants of the cancer. The abundance of Firmicutes
to the clear detriment of Proteobacteria was the most noticeable
result in our patients, and this result was  consistent in all sam-
ples. Proteobacteria dominance in health lung microbiota, especially
Pseudomonas, has been also previously corroborated.5,6,23 Higher
concentrations of Streptococcus, Blautia, Akkermansia, and Rothia
were observed in patients, but Streptococcus abundance was con-
sistently the major marker linked to lung cancer. This fact has
been previously reported in saliva,5 sputum,20,24 bronchoalveo-
lar lavage,5 lung tissue,7 and protected specimen brushing.6,21 The
exhaustive phylogenetic analysis of ASVs allows us to suggest thatentral Lung Cancer With Streptococcal Enrichment as a Possible
/j.arbres.2020.05.034
the streptococcal variants present in lung tissue are similar to those
found in saliva or faeces. New studies including Streptococcus cul-
tures and molecular characterization of the species are needed to
decipher whether oral lineages are different from those found in
ARTICLE IN PRESSG ModelARBRES-2525; No. of Pages 9

















ig. 4. Streptococcal abundance (A); ROC curves of the relative Streptococcus abun
icrobiota in controls and in patients (C).
he lungs or faeces and thus establish whether there are any mark-
rs truly associated with lung cancer, as occurs with Streptococcus
allolyticus subsp. gallolyticus and colorectal carcinoma.10,25
There is increasing evidence of a link between Streptococcus
nd lung cancer. Recently, Tsay et al.21 detected Streptococcus and
eillonella enrichment in the lower airways with ERK and PI3K
athways upregulation – an early event that contributes to cell
roliferation, survival and tissue invasion – combining microbiome
nd transcriptomic signatures. The major question that a remains
o be answered is whether the abundance of streptococci is a cause
r consequence of the tumour process.26 Streptococcus is a natural
nhabitant of the oral cavity, which is connected to the lower res-
iratory tract by the larynx and trachea, and the oral/lung bacterialPlease cite this article in press as: Bello S, et al. Core Microbiota in C
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016
xchange could occur via microaspirations.6,21,23
Microaspiration events are common, but their frequency is sig-
ificantly increased in chronic inflammatory airway diseases,23 to discriminate patients from controls (B), and distance between saliva and lung
inducing Th17 lymphocytes, as well as expression of inflammatory
cytokines (as IL-1, IL-1 and IL-17). IL-23/IL-17 axis alteration is
well known in the pathogenesis of both autoimmune diseases and
tumours, and Streptococcus mitis facilitate the cancer development
and expansion by induction of IL-1, IL-6, IL-10 and IL-23 tran-
scription, Th17 activation, and an increased immune checkpoint
PD-L1 expression.27 Lung resident  T cells with protective roles or
pro-tumorigenic functions in cancer have been recently discovered,
and local lung microbiota, including Streptococcus, can provoke
inflammation and tumour cell proliferation via lung resident 
T cells activation.28 Our results demonstrated a global streptococ-
cal enrichment in patients with cancer that affected more than just
the respiratory tract, supporting the idea that microorganisms canentral Lung Cancer With Streptococcal Enrichment as a Possible
/j.arbres.2020.05.034
orchestrate the balance between tumour-promoted inflammation
and anti-tumour immunity depending on the specific microenvi-
ronment.
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Fig. 6. Statistical differences (LEfSE) of the bacterial microbiota between pati
Streptococcal relative abundance in bronchial biopsies was
 good predictor of lung cancer, but unfortunately was not
eproducible in saliva. ROC curves suggested the contralateral
ronchi as the best sample (90.9% sensitivity and 83.3% specificity;
UC = 0.897). Other authors found similar results in protected spec-
men brushing samples (87.5% of sensitivity and 55.6% specificity,
UC = 0.693).6 The proportional abundance of Streptococcus should
e validated in the early stages of lung cancer with subsequent
ollow-up to corroborate their potential use as biomarker. Along
hese lines, the intestinal enrichment of Streptococcus should be
xhaustively explored to identify lung cancer markers in faeces.
The  intestinal and the respiratory ecosystems harbour a diverse
nd abundant microbiota, but some particularities distinguish both
cosystems. Food intake favours a higher rate of microbial repro-
uction increasing the total mass that is significantly reduced after
efecation. On the contrary, nutritional sources for bacteria in the
irway are limited to mucus and cellular debris, while clearance is
arried out by the ciliary system and the immune system, partic-
larly by macrophages. Lung microbiota core, which is composed
y those taxa that are present in >95% of individuals, had not yet
een defined. We  have implemented new computational strate-
ies to define the lung microbiota core, which had not previouslyPlease cite this article in press as: Bello S, et al. Core Microbiota in C
Diagnostic Marker. Arch Bronconeumol. 2020. https://doi.org/10.1016
een defined. Our main results are the elevated alpha-diversity
f the bronchial microbiota in comparison with saliva or faeces,
nd the dominance of Pseudomonas in controls. Presence of thisnd controls in bronchi and saliva. Only taxa with an LDA score > 4 are shown.
particular  genus is linked to cystic fibrosis, being the major
pathogen that decreases the respiratory functionality within a
pathogenic colonization in those patients. However, the lack of
respiratory symptoms reduces the potential pathogenic role of
Pseudomonas in healthy individuals, although more studies are
needed in that line.
The  mycobiome results were consistent with those obtained
for bacteria. The fungal community was  slightly richer and more
diverse in patients than in controls, although the contralateral
bronchus was  more similar to controls than to the affected coun-
terpart. The mycobiome of saliva and the affected bronchus from
patients matched perfectly, but differed in controls, again suggest-
ing that in patients with cancer the bronchial microbiota is the
result of a continuous exchange with that of the oral niche. In terms
of taxonomy, affected bronchi from patients had an enrichment of
the Basidiomycota phylum with higher populations of Malassezia
genus, whereas the enriched taxon in healthy individuals was the
Ascomycota phylum and the genera Candida and Saccharomyces, as
previously described.29 Although the public databases are increas-
ing exponentially, it is important to note that a major limitation
to describing the mycobiome is the lack of available taxonomic
records. As far as we know, this is the first description of the lungentral Lung Cancer With Streptococcal Enrichment as a Possible
/j.arbres.2020.05.034
mycobiome.
The main limitation of our work is that we cannot estimate
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icrobiota, mainly tobacco (all patients had been smokers but only
he half of the controls were), and COPD (12/25 patients). How-
ver, it has not been established yet if tobacco has a significant
nfluence on lung microbiota composition, and some important
tudies have shown contradictory results.16,30,31 Whereas severe
OPD has been linked with significant alterations in the lung micro-
iota composition,32,33 mild and moderate COPD (92% of our COPD
atients) has been associated with Streptococcus enrichment.33 This
nding might explain the association of mild/moderate COPD and
ung cancer,34 although further studies are needed to confirm this
ssociation.
Additional limitations are the small number of patients, all of
hem from the same hospital, and the lack of other -omic analy-
es based on genetic expression. On the other hand, our strengths
nclude performing the first study of microbiota combined with
ycobiome of bronchial tissue obtained directly from tumour and
ontralateral bronchi (not adjacent to a resected tumour), as well as
erforming analysis of the connected ecosystems including saliva
nd faeces.
In  summary, patients with central lung cancer have a signifi-
antly different bronchial microbiota from controls, not restricted
o tumour-involved tissue, and probably conditioned by continu-
us microaspiration events from the oral cavity, more than by the
arcinogenic process. Lung cancer was associated with a consider-
ble enrichment of Streptococcus and we propose that this feature
ould be used for the screening, diagnosis of this pathology. Lung
ycobiota differ considerably in control individuals, and there are
issimilarities in patients between the affected and the contralat-
ral bronchi. An innovative bioinformatics strategy used in this
tudy has allowed us to define healthy individuals’ the bronchial
ore microbiota, which is dominated by a non-pathogenic coloniza-
ion of Pseudomonas.
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